1. Home
  2. MBBC vs CVM Comparison

MBBC vs CVM Comparison

Compare MBBC & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MBBC

Marathon Bancorp Inc.

BUY

Current Price

$13.76

Market Cap

40.2M

Sector

Finance

ML Signal

BUY

Logo Cel-Sci Corporation

CVM

Cel-Sci Corporation

HOLD

Current Price

$3.20

Market Cap

32.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBBC
CVM
Founded
1902
1983
Country
United States
United States
Employees
35
N/A
Industry
Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.2M
32.4M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
MBBC
CVM
Price
$13.76
$3.20
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
12.0K
57.1K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$264,033.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$47.11
N/A
Revenue Growth
N/A
65.45
52 Week Low
$9.94
$0.23
52 Week High
$14.64
$13.48

Technical Indicators

Market Signals
Indicator
MBBC
CVM
Relative Strength Index (RSI) 61.62 37.82
Support Level $12.93 $3.18
Resistance Level N/A $4.84
Average True Range (ATR) 0.41 0.36
MACD 0.07 -0.10
Stochastic Oscillator 99.47 2.50

Price Performance

Historical Comparison
MBBC
CVM

About MBBC Marathon Bancorp Inc.

Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.

About CVM Cel-Sci Corporation

CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.

Share on Social Networks: